Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-4642 Injection and other drugs have received clinical trial approval.

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced recently that the company and its subsidiaries, Suzhou Shengdia Biopharmaceutical Co., Ltd., Shanghai Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Shanghai Shengdi Pharmaceutical Co., Ltd. have received approval from the National Medical Products Administration (referred to as the "NMPA") to conduct clinical trials on HRS-4642 injection, SHR-1701 injection, SHR-7367 injection, SHR-8068 injection, Atezolizumab injection, Bevacizumab injection, SHR-A2102 injection, Apatinib capsules, and Hydroxyethyl sulfonated Dalcetrapib tablets. The clinical trials will be carried out soon, specifically a Phase I/II study on the safety, tolerance, and effectiveness of a combination of HRS-4642 with other anti-tumor drugs in solid tumor subjects.